Compare EIG & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EIG | HROW |
|---|---|---|
| Founded | 2000 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 928.6M | 1.0B |
| IPO Year | 2006 | 2008 |
| Metric | EIG | HROW |
|---|---|---|
| Price | $47.67 | $27.51 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | $54.00 | ★ $63.00 |
| AVG Volume (30 Days) | 143.7K | ★ 544.1K |
| Earning Date | 10-28-2026 | 11-09-2026 |
| Dividend Yield | ★ 2.88% | N/A |
| EPS Growth | N/A | ★ 71.43 |
| EPS | ★ 2.73 | N/A |
| Revenue | ★ $858,700,000.00 | N/A |
| Revenue This Year | N/A | $28.41 |
| Revenue Next Year | N/A | $58.14 |
| P/E Ratio | $17.35 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $37.44 | $25.76 |
| 52 Week High | $53.51 | $54.98 |
| Indicator | EIG | HROW |
|---|---|---|
| Relative Strength Index (RSI) | 42.59 | 41.61 |
| Support Level | $41.49 | $26.96 |
| Resistance Level | $51.18 | $30.28 |
| Average True Range (ATR) | 1.79 | 1.31 |
| MACD | -0.39 | 0.07 |
| Stochastic Oscillator | 34.41 | 41.37 |
Employers Holdings Inc is a provider of workers' compensation insurance and services focused on small and mid-sized businesses engaged in low-to-medium hazard industries. Its customers are employers, and the insurance premiums that those employers pay to account for company revenue. Substantially all of the remaining revenue is generated through investments. The company operates exclusively in the United States, and it generates more than half of its business in California. By industry, the company has exposure to restaurants, which account for roughly a fourth of the total premiums the company earns. It operates as a single reportable segment, Insurance Operations through its wholly owned subsidiaries.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.